Vallon Pharmaceuticals Reports Additional Pharmacokinetic and Pharmacodynamic Data from SEAL Study of ADAIR
May 12, 2022 08:30 ET
|
Vallon Pharmaceuticals Inc.
PHILADELPHIA, PA, May 12, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the...
Vallon Pharmaceuticals Announces Issuance of Japanese Patent Covering Composition of Matter and Methods of Manufacturing for ADAIR
May 11, 2022 08:35 ET
|
Vallon Pharmaceuticals Inc.
PHILADELPHIA, PA, May 11, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the...
Vallon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 09, 2022 16:05 ET
|
Vallon Pharmaceuticals Inc.
PHILADELPHIA, PA, May 09, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the...
Vallon Pharmaceuticals Announces Review of Strategic Alternatives
April 22, 2022 08:00 ET
|
Vallon Pharmaceuticals Inc.
Philadelphia, PA, April 22, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the...
Vallon Pharmaceuticals to Participate at the 5th Annual Neuroscience Innovation Forum
March 23, 2022 08:00 ET
|
Vallon Pharmaceuticals Inc.
David Baker, President and CEO of Vallon to participate in the virtual Advances in Neuropsychiatry Panel, today, March 23rd at 9:00 AM ET Philadelphia, PA, March 23, 2022 (GLOBE NEWSWIRE) --...
Vallon Pharmaceuticals Announces Topline Results of its Pivotal SEAL Study for Lead Program, ADAIR, for the Treatment of ADHD
March 21, 2022 07:00 ET
|
Vallon Pharmaceuticals Inc.
– Study did not meet primary endpoint of significant reduction in Emax Drug Liking for ADAIR vs reference dextroamphetamine, although a trend in favor of ADAIR was observed (p=0.16) – All...
Vallon Pharmaceuticals Announces Appointment of Meenu Karson to Board of Directors
February 28, 2022 16:05 ET
|
Vallon Pharmaceuticals Inc.
Global biopharmaceutical industry senior executive with over 15 years of operational leadership with transactional and capital markets experience spanning both private and public large pharma and...
Vallon Pharmaceuticals Announces Issuance of U.S. Patent Covering ADAIR for the Treatment of Cognitive Impairment Associated with COVID-19
February 28, 2022 08:05 ET
|
Vallon Pharmaceuticals Inc.
- Company in ongoing discussions with a major academic research center for design and execution of proof-of-concept study evaluating ADAIR for the treatment of cognitive impairment associated with...
Vallon Pharmaceuticals Reports Fiscal Year 2021 Financial Results and Provides Business Update
February 14, 2022 16:15 ET
|
Vallon Pharmaceuticals Inc.
- Topline data for pivotal abuse study of the Company’s lead investigational program ADAIR expected this quarter - Second development program, ADMIR, continues to advance with...
Vallon Pharmaceuticals to Present at the Virtual Investor 2022 Top Picks Conference
January 20, 2022 08:35 ET
|
Vallon Pharmaceuticals Inc.
– Live video webcast presentation on Tuesday, January 25th at 9:00 AM ET PHILADELPHIA, PA, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the...